The findings reported in our study, namely a decrease in glycolytic flux and a restoration of PPP-related activity in VAT from APP/PS1 mice treated with Andrographolide, suggest that metabolic dysregulation in AD extends beyond the central nervous system. Here, APP is linked to Alzheimer disease.